Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 791

1.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group.

Lancet. 2019 Nov 14. pii: S0140-6736(19)32556-5. doi: 10.1016/S0140-6736(19)32556-5. [Epub ahead of print]

PMID:
31735560
2.

Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma.

Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P.

Clin Lymphoma Myeloma Leuk. 2019 Oct 10. pii: S2152-2650(19)32012-9. doi: 10.1016/j.clml.2019.09.625. [Epub ahead of print]

3.

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.

Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2019 Oct 31. pii: S1083-8791(19)30706-2. doi: 10.1016/j.bbmt.2019.10.024. [Epub ahead of print]

PMID:
31678537
4.

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.

Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.

Clin Cancer Res. 2019 Oct 31. doi: 10.1158/1078-0432.CCR-19-0647. [Epub ahead of print]

PMID:
31672767
5.

HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074.

Palumbo PJ, Zhang Y, Fogel JM, Guo X, Clarke W, Breaud A, Richardson P, Piwowar-Manning E, Hart S, Hamilton EL, Hoa NTK, Liulchuk M, Anandari L, Ha TV, Dumchev K, Djoerban Z, Hoffman I, Hanscom B, Miller WC, Eshleman SH.

PLoS One. 2019 Oct 10;14(10):e0223829. doi: 10.1371/journal.pone.0223829. eCollection 2019.

6.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2019 Oct 1. doi: 10.1038/s41409-019-0705-z. [Epub ahead of print] No abstract available.

PMID:
31576023
7.

Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.

Onyango-Makumbi C, Owora AH, Mwiru RS, Mwatha A, Young AM, Moodley D, Coovadia HM, Stranix-Chibanda L, Manji K, Maldonado Y, Richardson P, Andrew P, George K, Fawzi W, Fowler MG.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):377-385. doi: 10.1097/QAI.0000000000002145.

PMID:
31567725
8.

Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.

Mo CC, Richardson PG.

Br J Haematol. 2019 Sep 30. doi: 10.1111/bjh.16214. [Epub ahead of print] No abstract available.

PMID:
31566715
9.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG.

Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4.

PMID:
31456261
10.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
11.

Alcohol-related brain injury: Improving identification and management in an acute care setting.

Owens L, Thompson A, Patterson K, Richardson P.

Future Healthc J. 2019 Mar;6(Suppl 1):84. doi: 10.7861/futurehosp.6-1-s84. No abstract available.

12.

Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis.

Forrest EH, Storey N, Sinha R, Atkinson SR, Vergis N, Richardson P, Masson S, Ryder S, Thursz MR, Allison M, Fraser A, Austin A, McCune A, Dhanda A, Katarey D, Potts J, Verma S, Parker R, Hayes PC; STOPAH NLR Group.

Aliment Pharmacol Ther. 2019 Aug;50(4):442-453. doi: 10.1111/apt.15335. Epub 2019 Jul 17.

PMID:
31313853
13.

Controlling cellular distribution of drugs with permeability modifying moieties.

Richardson PL, Marin VL, Koeniger SL, Baranczak A, Wilsbacher JL, Kovar PJ, Bacon-Trusk PE, Cheng M, Hopkins TA, Haman ST, Vasudevan A.

Medchemcomm. 2019 Apr 18;10(6):974-984. doi: 10.1039/c8md00412a. eCollection 2019 Jun 1.

PMID:
31303996
14.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

15.

The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.

Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, Irving WL; HCV Research UK.

Aliment Pharmacol Ther. 2019 Jul;50(2):204-214. doi: 10.1111/apt.15296. Epub 2019 May 31.

PMID:
31149748
16.

Study protocol for a randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE trial).

Tripathi D, Hayes PC, Richardson P, Rowe I, Ferguson J, Devine P, Mathers J, Poyner C, Jowett S, Handley K, Grant M, Slinn G, Ahmed K, Brocklehurst P.

BMJ Open Gastroenterol. 2019 Apr 25;6(1):e000290. doi: 10.1136/bmjgast-2019-000290. eCollection 2019.

17.

Expanding Reactivity in DNA-Encoded Library Synthesis via Reversible Binding of DNA to an Inert Quaternary Ammonium Support.

Flood DT, Asai S, Zhang X, Wang J, Yoon L, Adams ZC, Dillingham BC, Sanchez BB, Vantourout JC, Flanagan ME, Piotrowski DW, Richardson P, Green SA, Shenvi RA, Chen JS, Baran PS, Dawson PE.

J Am Chem Soc. 2019 Jun 26;141(25):9998-10006. doi: 10.1021/jacs.9b03774. Epub 2019 Jun 12.

PMID:
31136164
18.

Towards a better understanding of monoclonal gammopathy of renal significance.

Bianchi G, Richardson PG.

Br J Haematol. 2019 Sep;186(5):653-654. doi: 10.1111/bjh.15989. Epub 2019 May 28. No abstract available.

PMID:
31134621
19.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators.

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

PMID:
31097405
20.

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. No abstract available.

PMID:
31043386

Supplemental Content

Loading ...
Support Center